Stockscreener 앱 받기
1.65
0.60%
-0.01
시간 외 거래:
1.65
전일 마감가:
$1.66
열려 있는:
$1.64
하루 거래량:
807.20K
Relative Volume:
0.60
시가총액:
$113.84M
수익:
$65,300
순이익/손실:
$-84.95M
주가수익비율:
-0.8535
EPS:
-1.9332
순현금흐름:
$-88.92M
1주 성능:
-1.79%
1개월 성능:
-4.07%
6개월 성능:
-28.26%
1년 성능:
-15.82%
1일 변동 폭
$1.60
$1.68
1주일 범위
$1.59
$1.77
52주 변동 폭
$1.30
$2.9789
Inovio Pharmaceuticals Inc Stock (INO) Company Profile
명칭
Inovio Pharmaceuticals Inc
전화
(858) 410-3134
주소
660 W. GERMANTOWN PIKE, PLYMOUTH MEETING, PA
Compare INO vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
INO
Inovio Pharmaceuticals Inc
|
1.65 | 114.53M | 65,300 | -84.95M | -88.92M | -1.9332 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.05 | 114.72B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
737.45 | 78.67B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
684.50 | 42.38B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.10 | 41.75B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
282.72 | 31.33B | 5.36B | 287.73M | 924.18M | 2.5229 |
Inovio Pharmaceuticals Inc Stock (INO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-09 | 개시 | Piper Sandler | Overweight |
| 2024-05-14 | 개시 | Stephens | Overweight |
| 2024-01-25 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2022-11-09 | 다운그레이드 | Maxim Group | Buy → Hold |
| 2022-11-01 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2022-07-19 | 재개 | RBC Capital Mkts | Sector Perform |
| 2022-05-11 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2022-01-21 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2021-12-29 | 재개 | Jefferies | Hold |
| 2021-09-10 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2021-06-24 | 개시 | Jefferies | Hold |
| 2021-03-23 | 개시 | BofA Securities | Neutral |
| 2021-02-12 | 개시 | Oppenheimer | Outperform |
| 2020-11-17 | 다운그레이드 | ROTH Capital | Neutral → Sell |
| 2020-11-10 | 업그레이드 | ROTH Capital | Sell → Neutral |
| 2020-09-28 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2020-09-28 | 업그레이드 | Maxim Group | Hold → Buy |
| 2020-07-01 | 다운그레이드 | Maxim Group | Buy → Hold |
| 2020-07-01 | 다운그레이드 | ROTH Capital | Neutral → Sell |
| 2020-06-29 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2020-06-26 | 다운그레이드 | Stifel | Buy → Hold |
| 2020-05-21 | 개시 | The Benchmark Company | Buy |
| 2020-04-30 | 다운그레이드 | ROTH Capital | Buy → Neutral |
| 2020-03-13 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2020-03-13 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-12-19 | 개시 | ROTH Capital | Buy |
| 2018-02-15 | 재확인 | Maxim Group | Buy |
| 2017-10-18 | 개시 | RBC Capital Mkts | Outperform |
| 2017-09-06 | 개시 | Citigroup | Buy |
| 2017-06-08 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
| 2017-05-24 | 재확인 | Maxim Group | Buy |
| 2017-03-16 | 업그레이드 | Maxim Group | Hold → Buy |
| 2017-03-16 | 다운그레이드 | Piper Jaffray | Overweight → Neutral |
모두보기
Inovio Pharmaceuticals Inc 주식(INO)의 최신 뉴스
Deadline Alert: Inovio Pharmaceuticals, Inc. (INO) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit - GlobeNewswire
Deadline Alert: Inovio Pharmaceuticals, Inc. (INO) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit - GlobeNewswire Inc.
INO Investors Have Opportunity to Lead Inovio Pharmaceuticals, Inc. Securities Fraud Lawsuit with the Schall Law Firm - GlobeNewswire
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Q4 2025 Earnings Call Transcript - Insider Monkey
Inovio stock up on earnings, pipeline progress - MSN
Inovio Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
INO DEADLINE: ROSEN, A TOP-RANKED LAW FIRM, Encourages Inovio Pharmaceuticals Inc. Investors ... - Bluefield Daily Telegraph
INO CLASS ACTION NOTICE: Faruqi & Faruqi, LLP Reminds Inovio Pharmaceuticals (INO) ... - Bluefield Daily Telegraph
LEVI & KORSINSKY, LLP: APRIL 7, 2026 -- DEADLINE TO SEEK LEAD PLAINTIFF ROLE IN INOVIO PHARMACEUTICALS SECURITIES CLASS ACTION - PR Newswire
Equities Analysts Set Expectations for INO Q1 Earnings - MarketBeat
INOVIO to Present DNA Medicine Data at Two Scientific Conferences - MyChesCo
Inovio Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
INO SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Inovio Pharmaceuticals (INO) Investors of Securities Class Action Deadline on April 7, 2026 - PR Newswire
Inovio (INO) Q4 2025 Earnings Call Transcript - The Globe and Mail
INO SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Inovio Pharmaceuticals (INO) Investors of Securities Class Action Deadline on April 7, 2026 (2026-03-17) - Seeking Alpha
Holzer & Holzer, LLC Reminds Investors of April 7, 2026 - GlobeNewswire
Inovio Pharmaceuticals Q4 2025 earnings preview - MSN
DEADLINE ALERT for TCPC, ORCL, PSFE, and INO: The Law - GlobeNewswire
INO INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Inovio Pharmaceuticals, Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
INO Shareholder Alert: April 7, 2026 Lead Plaintiff Deadline in Inovio Pharmaceuticals, Inc. Securities Class Action Lawsuit -- The Gross Law Firm - PR Newswire
Inovio Pharmaceuticals Inc. stock underperforms Monday when compared to competitors - MarketWatch
Inovio Pharmaceuticals, Inc. (INO) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - PR Newswire
Levi & Korsinsky, LLP: CEO and CFO Named as Control Person Defendants in Inovio Pharmaceuticals Securities Action - GlobeNewswire
Inovio Pharmaceuticals (INO) Reports Q1 Loss, Tops Revenue Estimates - MSN
Inovio Investors Urged to Join Securities Fraud Lawsuit - National Today
Bronstein, Gewirtz & Grossman LLC Urges Inovio - GlobeNewswire
Portnoy Law Firm Announces Class Action on Behalf of Inovio Pharmaceuticals, Inc. Investors - GlobeNewswire
INOVIO Pharmaceuticals spotlights INO-3107 potential in HPV-related cancer treatment at Eurogin - Traders Union
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Receives Consensus Rating of "Hold" from Analysts - MarketBeat
Layoff Tracker: Inovio Slims Down as Lead Asset Nears Market - BioSpace
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Inovio - GlobeNewswire
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Inovio Pharmaceuticals Inc. Investors to Secure ... - Caledonian Record
Boxer Capital Management LLC Purchases New Shares in Inovio Pharmaceuticals, Inc. $INO - MarketBeat
Inovio Stock Up On Earnings, Pipeline Progress - Sahm
Inovio Pharmaceuticals (NASDAQ:INO) Upgraded at Wall Street Zen - MarketBeat
INO SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Inovio Pharmaceuticals, Inc. Stockholders with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Inovio Pharmaceuticals Inc. stock underperforms Friday when compared to competitors - MarketWatch
Inovio cut 16% of workforce over the past year as FDA decision looms on drug application - The Business Journals
Inovio Pharmaceuticals, Inc. 2025 Q4ResultsEarnings Call Presentation (NASDAQ:INO) 2026-03-13 - Seeking Alpha
User - The Chronicle-Journal
INO Shareholder Alert: Investors With Losses May Seek to - GlobeNewswire
Inovio Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Inovio Pharmaceuticals Inc reports results for the quarter ended December 31Earnings Summary - TradingView
INOVIO Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights - Sahm
INO Stock Price, Quote & Chart | INOVIO PHARMACEUTICALS INC (NASDAQ:INO) - ChartMill
Inovio: Q4 Earnings Snapshot - theheraldreview.com
Inovio Pharmaceuticals Inc (INO) Q4 2025 Earnings Call Highlight - GuruFocus
Inovio Pharmaceuticals (INO) Advances BLA Review for INO-3107 - GuruFocus
Inovio Pharmaceuticals Q4 Earnings Call Highlights - MarketBeat
INO: INO-3107 BLA under FDA review; cash runway extended into Q4 2026 amid focused pipeline progress - TradingView
Earnings call transcript: Inovio Pharmaceuticals’ Q4 2025 results highlight cost reductions - Investing.com
Inovio Pharmaceuticals Inc (INO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.20%
0.06%
자본화:
|
볼륨(24시간):